Guggenheim Reiterates Buy on Eloxx Pharma, Maintains $43 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.2%

Neg 0% Neu 87.2% Pos 0%

Guggenheim analyst Vamil Divan reiterates Eloxx Pharma (NASDAQ:ELOX) with a Buy and maintains $43 price target.

Comments

No comments yet. Be the first!